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Multiple myeloma is characterized by the 
malignant proliferation of clonal plasma 
cells producing monoclonal paraproteins, 
leading to multi-organ damage. On the 
other hand monoclonal B-cell 
lymphocytosis (MBCL) is characterized by 
the malignant proliferation of clonal B-
lymphocytes, with potential to develop into 
chronic lymphocytic leukemia (CLL) or small 
lymphocytic lymphoma (SLL). CLL/SLL can 
result in visceromegaly, anemia, 
thrombocytopenia, fevers, night sweats 
and unintentional weight loss. Literature 
review demonstrates these two malignant 
clonal bone marrow disorders are most 
frequently seen independently in 
patients(1); however, we report one rare 
diagnostic challenge where both clonal 
disorders were identified in a single patient 
concurrently.
A 64-year-old man initially presented with 
worsening back pain. Thoracic spine x-ray 
revealed a T11 compression fracture, 




Bone Marrow Wars: Attack of the Clones
DISCUSSION
This patient case serves to demonstrate 
the importance of maintaining a broad 
differential when approaching 
hematological problems; It also 
underlines the necessity for a complete 
diagnostic evaluation to identify rare 
clinical conundrums such as with our 
patient, allowing for proper and timely 
treatment. While we use “Occam’s razor” 
to explain multiple problems with a single 
unifying diagnosis, the rare possibility of 
divergent diagnosis is to always be 
entertained.
(1) Alley CL1, Wang E, Dunphy CH, et al., 
Diagnostic and clinical considerations in 
concomitant bone marrow involvement by 
plasma cell myeloma and chronic lymphocytic 
leukemia/monoclonal B-cell lymphocytosis: a 
series of 15 cases and review of literature. Arch 
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Complete blood count revealed a white blood cell count of 7.3 K/uL with 54% lymphocyte 
predominance and peripheral smear demonstrated a population of small lymphocytes with 
round nuclei and an atypical chromatin pattern suggestive of CLL/MBCL. Flow cytometry 
revealed a monoclonal B-cell CD5 positive, CD23 positive, CD10 negative population with an 
absolute count of 1.6 K/uL. Due to the instability and pain associated with the spinal 
fracture, patient had kyphoplasty performed and intraoperative bone biopsies were taken 
from both T11 and T12 vertebrae. Interestingly each bone biopsy revealed involvement by 
both a kappa-light chain restricted plasma cell neoplasm, ranging from 15% to 30% 
cellularity, as well as a CD5-positive B-cell lymphocyte population. It suggested two 
concurrent but pathologically distinct pathologies including plasma cell myeloma and a 
separate B-cell lymphoproliferative disorder with immunophenotypic features suggestive of 
CLL/MBCL. Bone marrow biopsy was performed for definitive evaluation and confirmed 
multiple myeloma with 15-20% kappa-restricted plasma cells identified, and also confirmed 
concurrent MBCL with CD5 and CD23-positive, kappa-restricted B-cells identified on bone 
marrow flow cytometry. Adding an additional layer of complexity, bone marrow molecular 
genetics revealed presence of a MYD88 mutation, raising concern for possible 
lymphoplasmacytic lymphoma (LPL). However, secondary pathologic review ruled out LPL, 
as the immunophenotypic pattern of the clonal B-cells was not consistent with that of LPL, 
and although the MYD88 mutation is predominantly seen in LPL, it has also been seen in a 
small percentage of CLL/SLL cases and exceedingly rarely described in MM as well. Serum 
protein electrophoresis with immunofixation, serum quantitative immunoglobulins and 
serum quantitative free light chain assay revealed findings consistent with IgG kappa 
multiple myeloma and systemic CT imaging was negative for any lymphadenopathy, 
confirming MBCL. Patient was started on first-line multiple myeloma systemic therapy for 
transplant eligible patients and has demonstrated an excellent response to treatment thus 
far.
CASE DESCRIPTION (continued)
